Cancer Genetics — Q3 2015 Earnings Presentation
11 slides from Cancer Genetics's earnings presentation, Nov 10, 2015
Slide 1: Q3 2015 Earnings Call
November 10, 2015 Q3 2015 Earnings Call
Slide 2: Forward-Looking Statements
Cancer Genetics, Inc. | NASDAQ: CGIX | Q3 2015 Earnings Call Forward-Looking Statements These slides contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in
Slide 3: 3rd Quarter 2015 Revenue Highlights
Cancer Genetics, Inc. | NASDAQ: CGIX | Q3 2015 Earnings Call 3rd Quarter 2015 Revenue Highlights $6.9M PROFORMA REVENUE WITH RESPONSE ACQUISITION 24% REVENUE GROWTHFROM Q3 2014 Q3 TOTAL REVENUE GREW FROM $3.2M TO 2014 2015 * The proforma revenue numbers above may not be indicative of the consolidate
Slide 4: Revenues By Category
Cancer Genetics, Inc. | NASDAQ: CGIX | Q3 2015 Earnings Call Revenues By Category 65% 29% 6% Q3 2015 $3.2 MN $4.0 MN BIOPHARMA SERVICES Continued growth in contracts for future – now $34 MN Entered into partnership with ICON to offer Cancer Genetics’ services $2.6 MN CLINICAL SERVICES Closed a
Slide 5: 3rd Quarter 2015 Financial Highlights
Cancer Genetics, Inc. | NASDAQ: CGIX | Q3 2015 Earnings Call 3rd Quarter 2015 Financial Highlights Q3 2015 revenues were $4.0 million, a 24% increase over Q3 2014 revenues of $3.2 million. Revenue from Biopharma Services grew 35% , Clinical Services decreased slightly by 7% and Discovery Service
Slide 6: Income Statement Items
Cancer Genetics, Inc. | NASDAQ: CGIX | Q3 2015 Earnings Call Income Statement Items ($ in Thousands) Q3 2015 Q3 2014 9 mos 2015 9 mos 2014 Revenue $4,000 $3,221 $12,556 $6,164 Gross Profit $897 $656 $3,213 $805 Gross Margin (%) 22% 20% 26% 13% Research & Development (R&D) $1,802 $1,390 $4,335 $3,093
Slide 7: Highlights of Response Genetics Acquisition
Cancer Genetics, Inc. | NASDAQ: CGIX | Q3 2015 Earnings Call Highlights of Response Genetics Acquisition Response Genetics is an oncology-focused central laboratory with a specialty in solid tumors headquartered in Los Angeles, CA. Closed on October 9, 2015 Core business in solid tumor molecular
Slide 8: Tissue of Origin Competitor Comparison
Cancer Genetics, Inc. | NASDAQ: CGIX | Q3 2015 Earnings Call Tissue of Origin® Competitor Comparison CRITERIA Tissue of Origin® CancerTYPE ID™ Cancer Origin Test™ EXTERN A L REVIE W FDA CLEARED Yes No No MEDICARE COVERED Yes Yes Yes PEER-REVIEWED PUBLICATIONS 23 21 6 V A L ID A T IO N STUD Y NUMBER
Slide 9: Proforma Revenue with Response Genetics
Cancer Genetics, Inc. | NASDAQ: CGIX | Q3 2015 Earnings Call Proforma Revenue with Response Genetics * The proforma revenue numbers above may not be indicative of the consolidated results in the future. Acquisition completed October 9, 2015. $6.6 $10.2 $12.6 $19.8 $16.7 $10.0 $26.4 $26.9 $22.6 2013
Slide 10: Expense Synergies for Response Acquisition
Cancer Genetics, Inc. | NASDAQ: CGIX | Q3 2015 Earnings Call Expense Synergies for Response Acquisition Management estimates expense savings of more than $5 million in the first year of acquisition Consolidation of common functions including Billing, Accounting, Quality Assurance, Information Tech
Slide 11: The Oncology Diagnostics Partner From Bench to Bedside
THE ONCOLOGY DIAGNOSTICS PARTNER FROM BENCH TO BEDSIDE CGI Headquarters 201 Route 17 North Rutherford, NJ 07070 Phone: +1 201-528-9200 Fax: +1 201-528-9235 RUTHERFORD, NJ Research Triangle Park 133 Southcenter Court Morrisville, NC 27569 Phone: +1 919-465-0100 Fax: +1 919-465-0554 RALEIGH, NC LOS AN